Provided by Tiger Trade Technology Pte. Ltd.

BOAN BIOTECH

3.030
+0.1404.84%
Volume:424.60K
Turnover:1.25M
Market Cap:1.86B
PE:244.12
High:3.065
Open:2.890
Low:2.800
Close:2.890
52wk High:12.880
52wk Low:2.400
Shares:614.00M
HK Float Shares:614.00M
Volume Ratio:0.30
T/O Rate:0.07%
Dividend:- -
Dividend Rate:- -
EPS(LYR):0.012
ROE:-4.11%
ROA:-1.28%
PB:0.60
PE(LYR):244.12
PS:2.55

Loading ...

Shandong Boan Biotechnology launches share buyback program worth up to HK$ 200 million

Reuters
·
May 13

Shandong Boan Biotechnology Co Ltd - to Repurchase Shares up to HK$200 Mln

THOMSON REUTERS
·
May 13

Boan Biotech Maintains 622.33 Million Issued Shares and Meets Public‐Float Requirement in April 2026

Bulletin Express
·
May 07

BOAN BIOTECH's Stock Plummets Nearly 70% in Eight Months, Faces Critical Test to Maintain Stock Connect Eligibility

Stock News
·
May 01

博安生物营收破7.848亿元净利同比下滑 资本与研发投入助力长期增长

Bulletin Express
·
Apr 29

Boan Biotech’s 2025 ESG Report: Quad-ISO Certification, 50 Patents Granted and 13,468 tCO₂e Emissions

Bulletin Express
·
Apr 29

Shandong Boan Biotech publishes 2025 annual report

Reuters
·
Apr 29

Boan Biotech Announces Proposed Adoption of Restricted Share Unit Incentive Scheme for H Shares

Bulletin Express
·
Apr 28

BOAN BIOTECH Proposes Restricted Share Unit Incentive Scheme

Stock News
·
Apr 28

Shandong Boan Bio proposes H-share restricted share unit incentive scheme

Reuters
·
Apr 28

BOAN BIOTECH Secures CDE Approval to Launch Phase II Trial of BA1106 + BA1104 for Driver-Gene-Negative NSCLC

Bulletin Express
·
Apr 26

BOAN BIOTECH Receives CDE Acceptance for Phase II Trial Application of BA1106 Combined with BA1104 in Non-Small Cell Lung Cancer

Stock News
·
Apr 26

Shandong Boan says China CDE accepts Phase II trial application for BA1106-BA1104 combo in NSCLC

Reuters
·
Apr 26

Boan Biotech’s March Filing Shows Stable Share Base and Sufficient Public Float

Bulletin Express
·
Apr 08